Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 34Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Neoplasms 3Brain Neoplasms 3Skin Neoplasms 2Neoplasms by Site 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Noonan Syndrome 1Neoplasms, Squamous Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Lung Neoplasms 1Lung Diseases 1Laryngeal Neoplasms 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Erdheim-Chester Disease 1

Interventions

Magnetic Resonance Spectroscopy 4trametinib 3pembrolizumab 3Specimen Handling 3ulixertinib 2larotrectinib 2binimetinib 2Surveys and Questionnaires 2Radiosurgery 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1naporafenib 1lenvatinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × cobimetinib × Dermatologic × Clear all
NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡